Bridging the Biomarker Chasm With Interprofessional Molecular Tumor Boards-Reference-Cited by-同舟云学术

Bridging the Biomarker Chasm With Interprofessional Molecular Tumor Boards

Published:2023-08 Issue:8 Volume:19 Page:677-678
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

Kolesar Jill M.¹^ORCID,Arnold Susanne M.¹^ORCID,Ueland Frederick R.¹^ORCID,Evers B. Mark¹

Affiliation:

1. Jill M. Kolesar, PharmD, Division of Gynecologic Oncology, College of Medicine, University of Kentucky, Lexington, KY, Department of Pharmacy Practice and Science College of Pharmacy, University of Kentucky, Lexington, KY, Markey Cancer Center, University of Kentucky, Lexington, KY; Susanne M. Arnold, MD, Markey Cancer Center, University of Kentucky, Lexington, KY, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY; Frederick R. Ueland, MD, Division of Gynecologic...

Abstract

Molecular tumor boards including clinical pharmacists can overcome biomarker testing disparities.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.23.00215

Reference6 articles.

1. Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky

2. EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky

3. Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer?;JCO Oncology Practice;2023-09